跳到正文
原文
Endpoints News· @endpts · X·· 8 天前精选AI 评分62
AI 导读

Argenx宣布收购大环肽生物技术公司Unnatural Products,首付款为5.5亿美元,交易总价值最高可达11.5亿美元。此次收购将为Argenx的抗体工程能力补充口服肽技术。

推荐理由

Argenx以5.5亿美元首付款收购Unnatural Products,读者可借此了解抗体企业向口服肽领域延伸的交易结构。

正文

Argenx is buying macrocycle biotech Unnatural Products for $550M upfront, adding oral peptide capabilities to its antibody engineering. https://endpoints.news/argenx-to-acquire-unnatural-products-in-deal-worth-up-to-1-15b/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial

来源:Endpoints News · x.com